Opioid-induced Constipation Market Report

Europe Opioid-induced Constipation Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 18, 2020
  • PAGES：205
  • REPORT CODE：GMM553907
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Opioid-induced Constipation market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.3% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Opioid-induced Constipation Market Segmentations:

    By Player:

    • SLA Pharma

    • Daewoong

    • Valeant Pharmaceuticals International

    • AstraZeneca

    • Mundipharma

    • Sucampo

    • Merck

    • Takeda Pharmaceutical

    • Nektar Therapeutics

    • Bayer

    • Ironwood Pharmaceuticals

    • Shionogi

    • Theravance

    • Abbott

    • Johnson & Johnson

    • GlaxoSmithKline

    • Pfizer

    • Boehringer Ingelheim

    • Cosmo Pharmaceuticals

    • Synergy Pharmaceuticals

    • Daiichi Sankyo

    • Progenics Pharmaceuticals

    By Type:

    • Solid

    • Liquid

    By End-User:

    • Drugstore

    • Hospital

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Opioid-induced Constipation Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Opioid-induced Constipation Market Size and Growth Rate of Solid from 2014 to 2026

    • 1.3.2 Europe Opioid-induced Constipation Market Size and Growth Rate of Liquid from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Opioid-induced Constipation Market Size and Growth Rate of Drugstore from 2014 to 2026

    • 1.4.2 Europe Opioid-induced Constipation Market Size and Growth Rate of Hospital from 2014 to 2026

    • 1.4.3 Europe Opioid-induced Constipation Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Opioid-induced Constipation Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Opioid-induced Constipation by Major Types

      • 3.4.1 Market Size and Growth Rate of Solid

      • 3.4.2 Market Size and Growth Rate of Liquid

    4 Segmentation of Opioid-induced Constipation Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Opioid-induced Constipation by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Drugstore for Construction

      • 4.4.2 Market Size and Growth Rate of Hospital for Construction

      • 4.4.3 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Opioid-induced Constipation Production Analysis by Top Regions

    • 5.2 Europe Opioid-induced Constipation Consumption Analysis by Top Regions

    • 5.3 Europe Opioid-induced Constipation Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.3 France Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    6 Product Circulation of Opioid-induced Constipation Market among Top Countries

    • 6.1 Top 5 Export Countries in Opioid-induced Constipation Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Opioid-induced Constipation Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Opioid-induced Constipation Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Opioid-induced Constipation Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Opioid-induced Constipation Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Opioid-induced Constipation Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Opioid-induced Constipation Landscape Analysis

    • 7.1 Germany Opioid-induced Constipation Landscape Analysis by Major Types

    • 7.2 Germany Opioid-induced Constipation Landscape Analysis by Major End-Users

    8. UK Opioid-induced Constipation Landscape Analysis

    • 8.1 UK Opioid-induced Constipation Landscape Analysis by Major Types

    • 8.2 UK Opioid-induced Constipation Landscape Analysis by Major End-Users

    9. France Opioid-induced Constipation Landscape Analysis

    • 9.1 France Opioid-induced Constipation Landscape Analysis by Major Types

    • 9.2 France Opioid-induced Constipation Landscape Analysis by Major End-Users

    10. Italy Opioid-induced Constipation Landscape Analysis

    • 10.1 Italy Opioid-induced Constipation Landscape Analysis by Major Types

    • 10.2 Italy Opioid-induced Constipation Landscape Analysis by Major End-Users

    11. Spain Opioid-induced Constipation Landscape Analysis

    • 11.1 Spain Opioid-induced Constipation Landscape Analysis by Major Types

    • 11.2 Spain Opioid-induced Constipation Landscape Analysis by Major End-Users

    12. Poland Opioid-induced Constipation Landscape Analysis

    • 12.1 Poland Opioid-induced Constipation Landscape Analysis by Major Types

    • 12.2 Poland Opioid-induced Constipation Landscape Analysis by Major End-Users

    13. Russia Opioid-induced Constipation Landscape Analysis

    • 13.1 Russia Opioid-induced Constipation Landscape Analysis by Major Types

    • 13.2 Russia Opioid-induced Constipation Landscape Analysis by Major End-Users

    14. Switzerland Opioid-induced Constipation Landscape Analysis

    • 14.1 Switzerland Opioid-induced Constipation Landscape Analysis by Major Types

    • 14.2 Switzerland Opioid-induced Constipation Landscape Analysis by Major End-Users

    15. Turkey Opioid-induced Constipation Landscape Analysis

    • 15.1 Turkey Opioid-induced Constipation Landscape Analysis by Major Types

    • 15.2 Turkey Opioid-induced Constipation Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Landscape Analysis by Top Countries

      • 16.3.1 Denmark Opioid-induced Constipation Market Volume and Growth Rate

      • 16.3.2 Finland Opioid-induced Constipation Market Volume and Growth Rate

      • 16.3.3 Norway Opioid-induced Constipation Market Volume and Growth Rate

      • 16.3.4 Sweden Opioid-induced Constipation Market Volume and Growth Rate

      • 16.3.6 Iceland Opioid-induced Constipation Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Landscape Analysis by Top Countries

      • 17.3.1 Belgium Opioid-induced Constipation Market Volume and Growth Rate

      • 17.3.2 Netherlands Opioid-induced Constipation Market Volume and Growth Rate

      • 17.3.3 Luxembourg Opioid-induced Constipation Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Landscape Analysis by Top Countries

      • 18.3.1 Estonia Opioid-induced Constipation Market Volume and Growth Rate

      • 18.3.2 Latvia Opioid-induced Constipation Market Volume and Growth Rate

      • 18.3.3 Lithuania Opioid-induced Constipation Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 SLA Pharma

      • 19.1.1 SLA Pharma Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Daewoong

      • 19.2.1 Daewoong Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Valeant Pharmaceuticals International

      • 19.3.1 Valeant Pharmaceuticals International Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 AstraZeneca

      • 19.4.1 AstraZeneca Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Mundipharma

      • 19.5.1 Mundipharma Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Sucampo

      • 19.6.1 Sucampo Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Merck

      • 19.7.1 Merck Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Takeda Pharmaceutical

      • 19.8.1 Takeda Pharmaceutical Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Nektar Therapeutics

      • 19.9.1 Nektar Therapeutics Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Bayer

      • 19.10.1 Bayer Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Ironwood Pharmaceuticals

      • 19.11.1 Ironwood Pharmaceuticals Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Shionogi

      • 19.12.1 Shionogi Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Theravance

      • 19.13.1 Theravance Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Abbott

      • 19.14.1 Abbott Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Johnson & Johnson

      • 19.15.1 Johnson & Johnson Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 GlaxoSmithKline

      • 19.16.1 GlaxoSmithKline Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Pfizer

      • 19.17.1 Pfizer Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Boehringer Ingelheim

      • 19.18.1 Boehringer Ingelheim Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Cosmo Pharmaceuticals

      • 19.19.1 Cosmo Pharmaceuticals Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Synergy Pharmaceuticals

      • 19.20.1 Synergy Pharmaceuticals Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    • 19.21 Daiichi Sankyo

      • 19.21.1 Daiichi Sankyo Company Profile and Development Status

      • 19.21.2 Market Performance

      • 19.21.3 Product and Service Introduction

    • 19.22 Progenics Pharmaceuticals

      • 19.22.1 Progenics Pharmaceuticals Company Profile and Development Status

      • 19.22.2 Market Performance

      • 19.22.3 Product and Service Introduction

    The List of Tables and Figures (Totals 110 Figures and 151 Tables)

    • Figure Product Picture

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Solid Market, 2015 - 2026 (USD Million)

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Liquid Market, 2015 - 2026 (USD Million)

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Drugstore from 2014 to 2026

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure UK Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure France Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Opioid-induced Constipation Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Opioid-induced Constipation Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Opioid-induced Constipation

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Opioid-induced Constipation by Different Types from 2014 to 2026

    • Table Consumption Share of Opioid-induced Constipation by Different Types from 2014 to 2026

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Solid Market, 2015 - 2026 (USD Million)

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Liquid Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Opioid-induced Constipation by Different End-Users from 2014 to 2026

    • Table Consumption Share of Opioid-induced Constipation by Different End-Users from 2014 to 2026

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Drugstore from 2014 to 2026

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Hospital from 2014 to 2026

    • Figure Opioid-induced Constipation Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Opioid-induced Constipation Production by Major Regions

    • Table Europe Opioid-induced Constipation Production Share by Major Regions

    • Figure Europe Opioid-induced Constipation Production Share by Major Countries and Regions in 2014

    • Table Europe Opioid-induced Constipation Consumption by Major Regions

    • Table Europe Opioid-induced Constipation Consumption Share by Major Regions

    • Table Germany Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table UK Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table France Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Italy Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Spain Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Poland Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Russia Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Switzerland Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Turkey Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Opioid-induced Constipation Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Opioid-induced Constipation Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Opioid-induced Constipation Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Opioid-induced Constipation Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Germany Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Germany Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Germany Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table UK Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table UK Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table UK Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table UK Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table France Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table France Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table France Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table France Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Italy Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Italy Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Italy Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Italy Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Spain Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Spain Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Spain Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Spain Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Poland Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Poland Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Poland Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Poland Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Russia Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Russia Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Russia Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Russia Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Switzerland Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Switzerland Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Switzerland Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Turkey Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Turkey Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Turkey Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Opioid-induced Constipation Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Opioid-induced Constipation Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Opioid-induced Constipation Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Opioid-induced Constipation Market Volume and Growth Rate from 2014 to 2026

    • Table SLA Pharma Profiles

    • Table SLA Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table SLA Pharma Product benchmarking

    • Table SLA Pharma Strategic initiatives

    • Table SLA Pharma SWOT analysis

    • Table Daewoong Profiles

    • Table Daewoong Production, Value, Price, Gross Margin 2014-2019

    • Table Daewoong Product benchmarking

    • Table Daewoong Strategic initiatives

    • Table Daewoong SWOT analysis

    • Table Valeant Pharmaceuticals International Profiles

    • Table Valeant Pharmaceuticals International Production, Value, Price, Gross Margin 2014-2019

    • Table Valeant Pharmaceuticals International Product benchmarking

    • Table Valeant Pharmaceuticals International Strategic initiatives

    • Table Valeant Pharmaceuticals International SWOT analysis

    • Table AstraZeneca Profiles

    • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

    • Table AstraZeneca Product benchmarking

    • Table AstraZeneca Strategic initiatives

    • Table AstraZeneca SWOT analysis

    • Table Mundipharma Profiles

    • Table Mundipharma Production, Value, Price, Gross Margin 2014-2019

    • Table Mundipharma Product benchmarking

    • Table Mundipharma Strategic initiatives

    • Table Mundipharma SWOT analysis

    • Table Sucampo Profiles

    • Table Sucampo Production, Value, Price, Gross Margin 2014-2019

    • Table Sucampo Product benchmarking

    • Table Sucampo Strategic initiatives

    • Table Sucampo SWOT analysis

    • Table Merck Profiles

    • Table Merck Production, Value, Price, Gross Margin 2014-2019

    • Table Merck Product benchmarking

    • Table Merck Strategic initiatives

    • Table Merck SWOT analysis

    • Table Takeda Pharmaceutical Profiles

    • Table Takeda Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

    • Table Takeda Pharmaceutical Product benchmarking

    • Table Takeda Pharmaceutical Strategic initiatives

    • Table Takeda Pharmaceutical SWOT analysis

    • Table Nektar Therapeutics Profiles

    • Table Nektar Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Nektar Therapeutics Product benchmarking

    • Table Nektar Therapeutics Strategic initiatives

    • Table Nektar Therapeutics SWOT analysis

    • Table Bayer Profiles

    • Table Bayer Production, Value, Price, Gross Margin 2014-2019

    • Table Bayer Product benchmarking

    • Table Bayer Strategic initiatives

    • Table Bayer SWOT analysis

    • Table Ironwood Pharmaceuticals Profiles

    • Table Ironwood Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Ironwood Pharmaceuticals Product benchmarking

    • Table Ironwood Pharmaceuticals Strategic initiatives

    • Table Ironwood Pharmaceuticals SWOT analysis

    • Table Shionogi Profiles

    • Table Shionogi Production, Value, Price, Gross Margin 2014-2019

    • Table Shionogi Product benchmarking

    • Table Shionogi Strategic initiatives

    • Table Shionogi SWOT analysis

    • Table Theravance Profiles

    • Table Theravance Production, Value, Price, Gross Margin 2014-2019

    • Table Theravance Product benchmarking

    • Table Theravance Strategic initiatives

    • Table Theravance SWOT analysis

    • Table Abbott Profiles

    • Table Abbott Production, Value, Price, Gross Margin 2014-2019

    • Table Abbott Product benchmarking

    • Table Abbott Strategic initiatives

    • Table Abbott SWOT analysis

    • Table Johnson & Johnson Profiles

    • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

    • Table Johnson & Johnson Product benchmarking

    • Table Johnson & Johnson Strategic initiatives

    • Table Johnson & Johnson SWOT analysis

    • Table GlaxoSmithKline Profiles

    • Table GlaxoSmithKline Production, Value, Price, Gross Margin 2014-2019

    • Table GlaxoSmithKline Product benchmarking

    • Table GlaxoSmithKline Strategic initiatives

    • Table GlaxoSmithKline SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

    • Table Boehringer Ingelheim Profiles

    • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

    • Table Boehringer Ingelheim Product benchmarking

    • Table Boehringer Ingelheim Strategic initiatives

    • Table Boehringer Ingelheim SWOT analysis

    • Table Cosmo Pharmaceuticals Profiles

    • Table Cosmo Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Cosmo Pharmaceuticals Product benchmarking

    • Table Cosmo Pharmaceuticals Strategic initiatives

    • Table Cosmo Pharmaceuticals SWOT analysis

    • Table Synergy Pharmaceuticals Profiles

    • Table Synergy Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Synergy Pharmaceuticals Product benchmarking

    • Table Synergy Pharmaceuticals Strategic initiatives

    • Table Synergy Pharmaceuticals SWOT analysis

    • Table Daiichi Sankyo Profiles

    • Table Daiichi Sankyo Production, Value, Price, Gross Margin 2014-2019

    • Table Daiichi Sankyo Product benchmarking

    • Table Daiichi Sankyo Strategic initiatives

    • Table Daiichi Sankyo SWOT analysis

    • Table Progenics Pharmaceuticals Profiles

    • Table Progenics Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Progenics Pharmaceuticals Product benchmarking

    • Table Progenics Pharmaceuticals Strategic initiatives

    • Table Progenics Pharmaceuticals SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US